Search company, investor...

AlloCure

allocure.com

Stage

Series B - II | Dead

Total Raised

$48.72M

Last Raised

$1.5M

About AlloCure

AlloCure is a biotechnology company developing the use of cell therapy for the treatment of kidney disease. AlloCure's technology allows for the isolation and expansion of a specific population of mesenchymal stem cells obtained via conventional bone marrow donation. AlloCure's cells are not recognized by the immune system enabling them to be administered in an off-the-shelf fashion to any patient in need.

Headquarters Location

25 Corporate Drive Suite 360

Burlington, Massachusetts, 01803,

United States

801-583-8450

Missing: AlloCure's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: AlloCure's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing AlloCure

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AlloCure is included in 1 Expert Collection, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

AlloCure Patents

AlloCure has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/7/2012

Stem cells, Transcription factors, Biotechnology, Cell biology, Developmental biology

Application

Application Date

11/7/2012

Grant Date

Title

Related Topics

Stem cells, Transcription factors, Biotechnology, Cell biology, Developmental biology

Status

Application

Latest AlloCure News

Cell Therapy Global Market Report 2022: Market is Expected to Reach $19.75 Billion in 2026 at a CAGR of 16.5% - Long-term Forecast to 2031 - ResearchAndMarkets.com

May 20, 2022

The global cell therapy market is expected to grow from $9.02 billion in 2021 to $10.74 billion in 2022 at a compound annual growth rate (CAGR) of 19%. The market is expected to reach $19.75 billion in 2026 at a CAGR of 16.5%. Major players in the cell therapy market are Fibrocell Science Inc., JCR Pharmaceuticals Co. Ltd., PHARMICELL Co. Ltd., Osiris Therapeutics Inc., MEDIPOST, Vericel Corporation, Anterogen Co. Ltd., Kolon TissueGene Inc., Stemedica Cell Technologies Inc. and AlloCure. The cell therapy market consists of sales of cell therapy and related services. Cell therapy (CT) helps repair or replace damaged tissues and cells. A variety of cells are used for the treatment of diseases includes skeletal muscle stem cells, hematopoietic (blood-forming) stem cells (HSC), lymphocytes, mesenchymal stem cells, pancreatic islet cells, and dendritic cells. The main techniques used in cell therapy are stem cell therapy, cell vaccine, adoptive cell transfer (act), fibroblast cell therapy and chondrocyte cell therapy. Stem cell treatment, also known as regenerative medicine, uses stem cells or their derivatives to stimulate the healing response of sick, defective, or wounded tissue. The different types of therapies include allogeneic therapies, autologous therapies and is used in various applications such as oncology, cardiovascular disease (CVD), orthopedic, wound healing, others. The rising prevalence of chronic diseases contributed to the growth of the cell therapy market. According to the US Centers for Disease Control and Prevention (CDC), chronic disease is a condition that lasts for one year or more and requires medical attention or limits daily activities or both and includes heart disease, cancer, diabetes, and Parkinson's disease. Stem cells can benefit the patients suffering from spinal cord injuries, type 1 diabetes, Parkinson's disease (PD), heart disease, cancer, and osteoarthritis. For instance, according to the Center for Diseases Control and Prevention report in 2021, due to poor nutrition, and lack of physical activity, 6 in 10 adults in the USA are suffering from a chronic disease and 4 in 10 have two or more diseases. According to International Diabetes Federation, in 2019, globally 463 million people have diabetes and the number is expected to rise to 700 million by 2045 . According to the Parkinson's Foundation, every year, 60,000 Americans are diagnosed with PD, and more than 10 million people are living with PD worldwide. The growing prevalence of chronic diseases increased the demand for cell therapies and contributed to the growth of the market. The high cost of cell therapy hindered the growth of the cell therapy market. Cell therapies have become a common choice of treatment in recent years as people are looking for the newest treatment options. Although there is a huge increase in demand for cell therapies, they are still very costly to try. Therefore, the high cost of cell therapy restraints the growth of the cell therapy market. Key players in the market are strategically partnering and collaborating to expand the product portfolio and geographical presence of the company. Key Topics Covered:

AlloCure Frequently Asked Questions (FAQ)

  • Where is AlloCure's headquarters?

    AlloCure's headquarters is located at 25 Corporate Drive, Burlington.

  • What is AlloCure's latest funding round?

    AlloCure's latest funding round is Series B - II.

  • How much did AlloCure raise?

    AlloCure raised a total of $48.72M.

  • Who are the investors of AlloCure?

    Investors of AlloCure include SV Health Investors, Novo Holdings, Lundbeckfond Ventures and Qualifying Therapeutic Discovery Project.

  • Who are AlloCure's competitors?

    Competitors of AlloCure include Ambrx, Stemina Biomarker Discovery, Endocare, EpiCept, Aldagen and 12 more.

Compare AlloCure to Competitors

B
BresaGen

NovoCell, Inc./BresaGen is a stem cell engineering company dedicated to creating, delivering, and commercializing cell and drug therapies to treat diabetes and other chronic diseases. Novocell uses its cell encapsulation technology and expertise in cell implantation to develop a renewable source of specialized cells for the treatment of cellular diseases. Bresagen represents a division of Novocell's research operation.

K
Kardia Therapeutics

Kardia Therapeutics, Inc. is a research-stage biotechnology company focused on the development of cardiac regenerative therapies in the areas myocardial infarction and heart failure. Kardia Therapeutics' portfolio of technologies aims to utilize three related approaches: 1) Adult Cardiac Progenitor Cells, 2) Stem Cell Optimization Technologies, and 3) Homing/Growth Factor Therapies. Because the heart has a limited capacity for self-regeneration, Kardia's technologies have the potential to offer improved patient outcomes compared to existing treatments.

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

C
Corimmun

focused on the development of therapeutics for the treatment of congestive heart failure and atherosclerosis.

Regenetech Logo
Regenetech

Regenetech develops and offers intellectual property licenses in the area of Adult Stem Cell Expansion and therapeutic applications of adult stem cells. Regenetech uses a technology discovered by NASA in space experiments for growing three-dimensional (3D) stem cells in a weightless environment.

E
Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.